On June 19, 2009, Synairgen plc, a respiratory drug discovery company, completed the placing with institutional and other investors of approximately 29.5 million new ordinary shares at 17p per share and admission of those shares to trading on AIM. The placing raised gross proceeds of £6.35 million.
Synairgen was advised in this transaction by Fasken Martineau lawyers Nigel Gordon and Michael Kashis, assisted by trainee solicitor Raymond Xu.